Amgen’s AMG 420 yielded early but spectacular remissions, leaving Boehringer Ingelheim with egg on its face.
Other therapy areas take a back seat as the pharma industry continues to focus on cancer-focused licensing deals.
When the World Congress on Lung Cancer kicks off in Toronto later this month all eyes will be on Roche’s Impower-133 study.
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
In the Rewind trial, whose readout is due by year-end, Trulicity needs to avert heart complications and show clean safety to keep up with other glucose-lowering drugs.
September promises at least eight notable US marketing decisions, including a crucial lung cancer ruling for Roche’s Tecentriq and verdicts on Lilly and Teva’s competing…
The Ascend trial failure is a blow to the fish oil theory, but Amarin insists that it does not bode ill for its big readout.
Licensing deal activity holds up in first half of 2018 as biopharma continues to stay away from takeovers.
Featuring at the European Society of Cardiology meeting, which kicks off this weekend in Munich, are results with tafamidis, Xarelto and fish oil supplements.